Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors

SGLT-2 inhibitors (SGLT-2Is) have significantly improved cardio-renal outcomes and are preferred agents in people with cardiovascular diseases, heart failure, and diabetic kidney disease. Similarly, GLP-1 receptor agonists (GLP-1RAs) have significantly improved atherosclerotic cardiovascular outcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Awadhesh Kumar, Singh, Ritu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210541/
https://www.ncbi.nlm.nih.gov/pubmed/35800411
http://dx.doi.org/10.4239/wjd.v13.i6.466

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210541/
https://www.ncbi.nlm.nih.gov/pubmed/35800411
http://dx.doi.org/10.4239/wjd.v13.i6.466

Ejemplares similares